Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma, a specific type of brain tumor, are being filed against the responsible pharmaceutical companies. A primary focus of these legal cases will be why the Depo-Provera drug label in the US does not include any warnings about the increased risk of this brain tumor. Meanwhile, the Depo-Provera drug labels used in the European Union (EU) and the United Kingdom (UK) have warned about meningioma for many years.
Essentially, these Depo-Provera brain tumor lawsuits are based on the general contention that the pharmaceutical companies knew that Depo-Provera was unreasonably unsafe and unfit for use due to the “product defect” of an increased risk of intracranial meningioma associated with Depo-Provera. And to make things worse, those companies have failed to warn about meningioma to women and their doctors here in the US.
Here are some of the relevant allegations found in the Complaints filed for these Depo-Provera brain tumor lawsuits:
- To date, the US Depo-Provera drug label does not mention the increased risk to patients of developing intracranial meningiomas, even though the European Union (EU) and the United Kingdom (UK) drug labels list meningioma under the “special warnings and precautions for use” section and advise patients to speak with their doctors before using Depo-Provera if they have a history of meningioma.
- Moreover, the Canadian drug label for Depo-Provera has listed “meningioma” among its “Post-Market Adverse Drug Reactions” since at least 2015.
- Several scientific studies — dating back to the 1980s and during the decades since — have established that progesterone, its synthetic analog progestin, and Depo-Provera in particular, cause or substantially contribute to the development of intracranial meningioma, a type of brain tumor.
We are investigating Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma and want legal compensation from the responsible pharmaceutical companies.
[View article at original source]Depo-Provera Contraceptive Injection
Free Case Evaluation
Strictly Confidential, No Obligation